You need JavaScript to view this

Relative cerebral blood volume measurements of low-grade gliomas predict patient outcome in a multi-institution setting

Abstract

Background/purpose: The prognostic value of defining subcategories of gliomas is still controversial. This study aims to determine the utility of relative cerebral blood volume (rCBV) in predicting clinical response in patients with low-grade glioma at multiple institutions. Materials and methods: Sixty-nine patients were studied with dynamic susceptibility contrast-enhanced perfusion MRI at two institutions. The pathologic diagnoses of the low-grade gliomas were 34 astrocytomas, 20 oligodendroglioma, 9 oligoastrocytomas, 1 ganglioglioma and 5 with indeterminate histology. Wilcoxon tests were used to compare patients in different response categories with respect to baseline rCBV. Kaplan-Meier curve and log-rank tests were used to predict the association of rCBV with time to progression. Results: At both institutions, patients with an adverse event (progressive disease or death) had a significantly higher baseline rCBV than those without (complete response or stable disease) (p value = 0.0138). The odds ratio for detecting an adverse event when using rCBV was 1.87 (95% confidence interval: 1.14-3.08). rCBV was significantly negatively associated with time to progression (p = 0.005). The median time to progression among subjects with rCBV > 1.75 was 365 days, while there was 95% confidence that the median time to progression was at least 889 days among subjects with  More>>
Authors:
Caseiras, Gisele B. , E-mail: g.brasil@ion.ucl.ac.uk; [1]  Chheang, Sophie; Babb, James; [2]  Rees, Jeremy H; [1]  Pecerrelli, Nicole; [2]  Tozer, Daniel J; Benton, Christopher; [1]  Zagzag, David; [3]  Johnson, Glyn; [2]  Waldman, Adam D; [1]  Imperial College of Science Technology and Medicine, London (United Kingdom)]; Jaeger, H R; [1]  Law, Meng [4] 
  1. Institute of Neurology, UCL, London SW1X 0HZ (United Kingdom)
  2. Department of Radiology, New York University Medical Center, New York, NY (United States)
  3. Department of Pathology and Neurosurgery, New York University Medical Center, New York, NY (United States)
  4. Department of Radiology and Neurosurgery, Mount Sinai Medical Center, New York, NY (United States)
Publication Date:
Feb 15, 2010
Product Type:
Journal Article
Resource Relation:
Journal Name: European Journal of Radiology; Journal Volume: 73; Journal Issue: 2; Other Information: DOI: 10.1016/j.ejrad.2008.11.005; PII: S0720-048X(08)00629-3; Copyright (c) 2008 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA)
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; ASTROCYTOMAS; BLOOD; BRAIN; DEATH; DIAGNOSIS; HISTOLOGY; NMR IMAGING; PATHOLOGY; PATIENTS
OSTI ID:
21324862
Country of Origin:
Netherlands
Language:
English
Other Identifying Numbers:
Journal ID: ISSN 0720-048X; EJRADR; TRN: NL10R1110066190
Availability:
Available from http://dx.doi.org/10.1016/j.ejrad.2008.11.005;INIS
Submitting Site:
NLN
Size:
page(s) 215-220
Announcement Date:
Aug 26, 2010

Citation Formats

Caseiras, Gisele B. , E-mail: g.brasil@ion.ucl.ac.uk, Chheang, Sophie, Babb, James, Rees, Jeremy H, Pecerrelli, Nicole, Tozer, Daniel J, Benton, Christopher, Zagzag, David, Johnson, Glyn, Waldman, Adam D, Imperial College of Science Technology and Medicine, London (United Kingdom)], Jaeger, H R, and Law, Meng. Relative cerebral blood volume measurements of low-grade gliomas predict patient outcome in a multi-institution setting. Netherlands: N. p., 2010. Web. doi:10.1016/j.ejrad.2008.11.005.
Caseiras, Gisele B. , E-mail: g.brasil@ion.ucl.ac.uk, Chheang, Sophie, Babb, James, Rees, Jeremy H, Pecerrelli, Nicole, Tozer, Daniel J, Benton, Christopher, Zagzag, David, Johnson, Glyn, Waldman, Adam D, Imperial College of Science Technology and Medicine, London (United Kingdom)], Jaeger, H R, & Law, Meng. Relative cerebral blood volume measurements of low-grade gliomas predict patient outcome in a multi-institution setting. Netherlands. https://doi.org/10.1016/j.ejrad.2008.11.005
Caseiras, Gisele B. , E-mail: g.brasil@ion.ucl.ac.uk, Chheang, Sophie, Babb, James, Rees, Jeremy H, Pecerrelli, Nicole, Tozer, Daniel J, Benton, Christopher, Zagzag, David, Johnson, Glyn, Waldman, Adam D, Imperial College of Science Technology and Medicine, London (United Kingdom)], Jaeger, H R, and Law, Meng. 2010. "Relative cerebral blood volume measurements of low-grade gliomas predict patient outcome in a multi-institution setting." Netherlands. https://doi.org/10.1016/j.ejrad.2008.11.005.
@misc{etde_21324862,
title = {Relative cerebral blood volume measurements of low-grade gliomas predict patient outcome in a multi-institution setting}
author = {Caseiras, Gisele B. , E-mail: g.brasil@ion.ucl.ac.uk, Chheang, Sophie, Babb, James, Rees, Jeremy H, Pecerrelli, Nicole, Tozer, Daniel J, Benton, Christopher, Zagzag, David, Johnson, Glyn, Waldman, Adam D, Imperial College of Science Technology and Medicine, London (United Kingdom)], Jaeger, H R, and Law, Meng}
abstractNote = {Background/purpose: The prognostic value of defining subcategories of gliomas is still controversial. This study aims to determine the utility of relative cerebral blood volume (rCBV) in predicting clinical response in patients with low-grade glioma at multiple institutions. Materials and methods: Sixty-nine patients were studied with dynamic susceptibility contrast-enhanced perfusion MRI at two institutions. The pathologic diagnoses of the low-grade gliomas were 34 astrocytomas, 20 oligodendroglioma, 9 oligoastrocytomas, 1 ganglioglioma and 5 with indeterminate histology. Wilcoxon tests were used to compare patients in different response categories with respect to baseline rCBV. Kaplan-Meier curve and log-rank tests were used to predict the association of rCBV with time to progression. Results: At both institutions, patients with an adverse event (progressive disease or death) had a significantly higher baseline rCBV than those without (complete response or stable disease) (p value = 0.0138). The odds ratio for detecting an adverse event when using rCBV was 1.87 (95% confidence interval: 1.14-3.08). rCBV was significantly negatively associated with time to progression (p = 0.005). The median time to progression among subjects with rCBV > 1.75 was 365 days, while there was 95% confidence that the median time to progression was at least 889 days among subjects with rCBV < 1.75. Conclusion: Our study suggests not only that rCBV measurements correlate well with time to progression or death, but also that the findings can be replicated across institutions, which supports the application of rCBV as an adjunct to pathology in predicting glioma biology.}
doi = {10.1016/j.ejrad.2008.11.005}
journal = []
issue = {2}
volume = {73}
place = {Netherlands}
year = {2010}
month = {Feb}
}